GHP July 2017

GHP / July 2017 27 NEWS , The humectants market is growing in accordance with the advancement of the bakery & confection- ery products, and functional & nu- tritional food & beverage industry. The rise in demand for humec- tants from industries such as food & beverage, oral & personal care products, animal feed, and phar- maceuticals is driving the market. The food & beverage segment, by application, dominated the hu- mectants market in 2016. Factors such as rise in health-conscious consumers, growth in aging pop- ulation, increase in consumer awareness regarding nutritious diet, and rise in consumer health concerns related to the consump- tion of high-calorie foods are ex- pected to drive the market in food & beverage segment. The oral & personal care products seg- ment is projected to grow at the second-highest CAGR during the forecast period, followed by the pharmaceuticals segment. The sugar alcohols segment dom- inated the humectants market in 2016, by type, owing to its better nutritional profile as humectants and its dominant usage in ma- jor end-use applications such as bakery and confectionery prod- ucts, fruits & vegetables, fruit & vegetable juices, oral & personal care products, pharmaceuticals, tobacco, plastics, and tanneries The Asia-Pacific region is project- ed to grow at the highest CAGR from 2017 to 2022, India being the fastest-growing market in the region. In India, diabetes and obesity are mostly associated with unhealthy food consumption habits. Awareness among sugar consumers in the country regard- ing its health risks has fuelled the growth of low- or zero-calorie foods that are manufactured us- ing polyols such as sorbitol, man- nitol, maltitol, and xylitol. Due to the rapid development of cosmetics and personal care industries, use of glycerine is growing at a higher pace. The other drivers fuelling the growth of glycerine are in the rising stand- ards of living, rapidly changing economies, and demand for re- fined glycerine for personal care & pharmaceutical products. For more informa- tion about this report visit research/3njz3h/humectants_ market Global Humectants Market to Reach $26.2 Billion by 2022 The ‘HumectantsMarket - Global Forecast to 2022’ report has beenadded toResearchand Markets’ offering. Thehumectantsmarket is projected to reach$26.27billionby2022, at a CAGRof 7.0%from2017, in terms of value. In terms of volume, themarket is projected to reach 14,741.6KTby2022, at aCAGRof 3.9%from2017. About Lenvatinib Lenvatinib, discovered and developed by Eisai, is an oral multikinase inhibitor of vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor receptor–alpha, and RET and KIT proto-oncogenes. Lenvatinib is approved in the EU and the US for specific patient populations: In the European Union lenvatinib is indicated: • Under the brand name Lenvima ® for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma (DTC) refractory to radioactive iodine (RAI). • Under the brand name Kisplyx® in combination with everolimus in the European Union for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted therapy. For more information about Eisai Co., Ltd., please visit